Author:
Lemoine LA,Segarra-Newnham M*
Publisher
Heighten Science Publications Corporation
Reference13 articles.
1. 1. Centers for Disease Control and Prevention. Viral Hepatitis: Hepatitis C Information. 2019.
2. 2. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2014; 61: 77-87. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25069599
3. 3. Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int. 2018; 12: 214-222. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29845496
4. 4. American Association for the Study of Liver Diseases, and Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2019
5. 5. Andres J, Lott S, Qureshi K. Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data. J Manag Care Spec Pharm. 2018; 24: 23-28. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29290174